Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Protocol: Use of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients With Persistent Babesia Microti Despite Prior Treatment

Next Previous
Trial Profile

Expanded Access Protocol: Use of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients With Persistent Babesia Microti Despite Prior Treatment

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 13 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tafenoquine (Primary)
  • Indications Babesiosis
  • Focus Expanded access; Therapeutic Use
  • Sponsors 60 Degrees Pharmaceuticals

Most Recent Events

  • 08 Jan 2025 According to a 60 Degrees Pharma media release, the first patient has been enrolled.
  • 09 Jul 2024 According to a 60 Degrees Pharma media release, company announced ethics approval of open label, expanded access program.
  • 03 Jul 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top